Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Amling

Showing results (131-140 of 199) with videos related to

Pageof 20
Sort By:
BJU International|April 4, 2017
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancerLauren E Howard, Daniel M Moreira, Amanda De Hoedt, et al.
Cancer|October 21, 2015
Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital DatabaseBrian T Hanyok, Lauren E Howard, Christopher L Amling, et al.
European Urology Focus|July 30, 2017
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH DatabaseColette A Whitney, Lauren E Howard, Edwin M Posadas, et al.
The Canadian Journal of Urology|November 2, 2006
Evaluation of mechanical bowel preparation methods in urinary diversion surgeryAllen F Morey, L Andrew Evans, R Clayton McDonough, et al.
Urology|June 19, 2007
Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men?John C Mavropoulos, Alan W Partin, Christopher L Amling, et al.
BJU International|May 27, 2015
Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?Ross M Simon, Lauren E Howard, Stephen J Freedland, et al.
Urology|March 18, 2003
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomyChristopher J Kane, Christopher L Amling, Peter A S Johnstone, et al.
Cancer|April 30, 2019
Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH databaseFarnoosh Nik-Ahd, Lauren E Howard, Adva T Eisenberg, et al.
Urology|July 24, 2017
Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical RecurrenceStephanie L Skove, Lauren E Howard, William J Aronson, et al.
Cancer|June 30, 2010
Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) DatabaseRobert J Hamilton, Lionel L Banez, William J Aronson, et al.
Pageof 20

Showing results (131-140 of 199) with videos related to

Sort By:
Pageof 20
BJU International|April 4, 2017
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancerLauren E Howard, Daniel M Moreira, Amanda De Hoedt, et al.
Cancer|October 21, 2015
Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital DatabaseBrian T Hanyok, Lauren E Howard, Christopher L Amling, et al.
European Urology Focus|July 30, 2017
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH DatabaseColette A Whitney, Lauren E Howard, Edwin M Posadas, et al.
The Canadian Journal of Urology|November 2, 2006
Evaluation of mechanical bowel preparation methods in urinary diversion surgeryAllen F Morey, L Andrew Evans, R Clayton McDonough, et al.
Urology|June 19, 2007
Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men?John C Mavropoulos, Alan W Partin, Christopher L Amling, et al.
BJU International|May 27, 2015
Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?Ross M Simon, Lauren E Howard, Stephen J Freedland, et al.
Urology|March 18, 2003
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomyChristopher J Kane, Christopher L Amling, Peter A S Johnstone, et al.
Cancer|April 30, 2019
Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH databaseFarnoosh Nik-Ahd, Lauren E Howard, Adva T Eisenberg, et al.
Urology|July 24, 2017
Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical RecurrenceStephanie L Skove, Lauren E Howard, William J Aronson, et al.
Cancer|June 30, 2010
Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) DatabaseRobert J Hamilton, Lionel L Banez, William J Aronson, et al.
Pageof 20